Astellas Pharma Inc. has recently made various significant announcements. New changes have been introduced to their Board of Directors and Management Structure. The company has reported better-than-expected Earnings, along with a surge in their fiscal 2024 core profit. They have partnered with YASKAWA to establish a joint venture focused on cell therapy manufacturing and signed a hefty gene therapy deal with AviadoBio Ltd. The company received U.S. FDA approval for expanded labels for IZERVAY and VYLOY for geographic atrophy and advanced gastric and GEJ cancer, respectively. An indictment occurred against an Astellas employee by China's prosecutors. The operations of their South San Francisco production plant will shut down. Astellas' first-in-class drug has been approved for rare gastrointestinal cancer. The company's sustainability reporting will benefit from their use of the IBM Envizi ESG Suite. Astellas continues to present scientific progress in advanced and hard-to-treat cancers and has opened a new Life Sciences Center in Cambridge, Massachusetts. The company's future remains innovative and insightful, with a revolutionary vision for creating breakthrough therapies.
Astellas Pharma Inc. News Analytics from Mon, 06 Nov 2023 08:00:00 GMT to Thu, 08 May 2025 23:57:23 GMT -
Rating 2
- Innovation 7
- Information 5
- Rumor -3
